Key facts
- Genexis Biotech’s last known valuation is $2.9M (Jul 2025).
- It has raised $470K; the latest was Seed Round ($470K) in Jul 2025.
- Notable investors include GVFL, Benzai10 Investment Fund, Humane Entrepreneurship Program.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Genexis Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Genexis Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genexis Biotech
Developer of biological components designed for research, therapeutic development, and industrial biotechnology applications. The company's platform includes precision-fermented recombinant proteins, serum-free cell culture media, and engineered growth factors, enabling biotechnology, cellular agriculture, and regenerative medicine sectors to access alternatives to traditional animal-derived inputs.
- Sector
- Healthcare
- HQ
- Vadodara, India
- Founded
- 2019
- Employees
- 9
- Website
- genexisbiotech.com/
- Ownership
- Privately Held (backing)
Genexis Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genexis Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genexis Biotech in its N-PORT filings yet. We sweep new filings monthly.